Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Stock Report

Market Cap: US$466.3m

Y-mAbs Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:YMAB Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Sep 24SellUS$1,264,650Thomas GadIndividual95,000US$13.47
26 Aug 24SellUS$73,450Joris Wiel WilmsIndividual5,000US$14.69
11 Jun 24SellUS$841,050Thomas GadIndividual70,000US$12.03
10 Jun 24SellUS$8,664Gérard BerIndividual722US$12.00
23 May 24SellUS$395,563Thomas GadIndividual32,351US$13.00
05 Mar 24SellUS$27,837Susan SmithIndividual1,682US$16.55
05 Mar 24SellUS$64,116Thomas GadIndividual3,900US$16.44
05 Mar 24SellUS$28,283Vignesh RajahIndividual1,711US$16.53
15 Dec 23SellUS$1,001,000Thomas GadIndividual150,000US$6.83
11 Dec 23BuyUS$890,411Wg Biotech ApsCompany127,549US$7.01
11 Dec 23BuyUS$44,232Wg Biotech ApsCompany6,455US$6.85
29 Nov 23BuyUS$309,477Wg Biotech ApsCompany51,837US$5.97
28 Nov 23BuyUS$521,294Wg Biotech ApsCompany93,187US$5.81

Insider Trading Volume

Insider Buying: YMAB insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of YMAB?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,178,2542.63%
Hedge Funds4,086,3469.12%
Private Companies4,559,23310.2%
VC/PE Firms6,059,62513.5%
General Public6,915,46315.4%
Institutions21,990,15549.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.

Top Shareholders

Top 25 shareholders own 76.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.2%
Wg Biotech Aps
4,559,233US$47.5m0%no data
9.12%
Paradigm Biocapital Advisors LP
4,086,346US$42.5m5.57%1.46%
7.36%
HBM Partners Ltd.
3,297,800US$34.3m0%3.48%
6.75%
BlackRock, Inc.
3,025,235US$31.5m2.94%no data
6.17%
Acorn Bioventures
2,761,825US$28.8m0%29.07%
4.9%
Sofinnova Investment, Inc.
2,194,278US$22.8m0%1.81%
4.54%
The Vanguard Group, Inc.
2,035,363US$21.2m3.99%no data
4.09%
Polar Capital Holdings Plc
1,831,000US$19.1m0%0.07%
3.24%
Cormorant Asset Management, LP
1,450,000US$15.1m0%0.7%
2.7%
State Street Global Advisors, Inc.
1,209,781US$12.6m50.4%no data
2.67%
Caligan Partners, LP
1,195,253US$12.4m105%3.69%
1.82%
Geode Capital Management, LLC
813,489US$8.5m6.25%no data
1.79%
Logos Global Management, L.P.
800,000US$8.3m0%0.97%
1.76%
D. E. Shaw & Co., L.P.
787,536US$8.2m-15%0.01%
1.54%
Pictet Asset Management Limited
687,980US$7.2m4.29%0.01%
1.39%
Claus Moller-San Pedro
622,928US$6.5m0%no data
1.24%
Boothbay Fund Management, LLC
557,429US$5.8m50.9%0.18%
1.07%
Dimensional Fund Advisors LP
477,664US$5.0m-1.4%no data
0.89%
Soleus Capital Management, L.P.
399,982US$4.2m-38.3%0.34%
0.75%
Northern Trust Global Investments
337,287US$3.5m6.13%no data
0.62%
Charles Schwab Investment Management, Inc.
279,577US$2.9m9.38%no data
0.61%
Citadel Advisors LLC
274,547US$2.9m4.89%no data
0.58%
Thomas Gad
260,112US$2.7m-21.7%no data
0.51%
Morgan Stanley, Investment Banking and Brokerage Investments
227,618US$2.4m26.7%no data
0.41%
Bo Kruse
184,977US$1.9m0%no data